JP2011518773A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011518773A5 JP2011518773A5 JP2011500800A JP2011500800A JP2011518773A5 JP 2011518773 A5 JP2011518773 A5 JP 2011518773A5 JP 2011500800 A JP2011500800 A JP 2011500800A JP 2011500800 A JP2011500800 A JP 2011500800A JP 2011518773 A5 JP2011518773 A5 JP 2011518773A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- subject
- composition
- hcc
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims description 52
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 41
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 41
- 101000620348 Homo sapiens Plasmalemma vesicle-associated protein Proteins 0.000 claims description 22
- 102100022427 Plasmalemma vesicle-associated protein Human genes 0.000 claims description 22
- 229920001184 polypeptide Polymers 0.000 claims description 21
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 21
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 21
- 239000000523 sample Substances 0.000 claims description 21
- 229940127089 cytotoxic agent Drugs 0.000 claims description 20
- 101150095995 Plvap gene Proteins 0.000 claims description 16
- 239000000203 mixture Substances 0.000 claims description 15
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 12
- 210000004185 liver Anatomy 0.000 claims description 11
- 239000002246 antineoplastic agent Substances 0.000 claims description 10
- 239000002254 cytotoxic agent Substances 0.000 claims description 10
- 231100000599 cytotoxic agent Toxicity 0.000 claims description 10
- 238000001802 infusion Methods 0.000 claims description 7
- 210000005228 liver tissue Anatomy 0.000 claims description 7
- 238000001361 intraarterial administration Methods 0.000 claims description 5
- 206010061309 Neoplasm progression Diseases 0.000 claims description 4
- 230000010109 chemoembolization Effects 0.000 claims description 4
- 230000000694 effects Effects 0.000 claims description 4
- 230000005747 tumor angiogenesis Effects 0.000 claims description 4
- 230000004614 tumor growth Effects 0.000 claims description 4
- 230000005751 tumor progression Effects 0.000 claims description 4
- 238000009007 Diagnostic Kit Methods 0.000 claims description 3
- 108020004711 Nucleic Acid Probes Proteins 0.000 claims description 3
- 238000001514 detection method Methods 0.000 claims description 3
- 239000002853 nucleic acid probe Substances 0.000 claims description 3
- 230000005740 tumor formation Effects 0.000 claims description 3
- 230000035508 accumulation Effects 0.000 claims description 2
- 238000009825 accumulation Methods 0.000 claims description 2
- 238000001727 in vivo Methods 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 238000000338 in vitro Methods 0.000 claims 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 8
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 8
- 239000005557 antagonist Substances 0.000 description 8
- 238000002965 ELISA Methods 0.000 description 7
- 238000011532 immunohistochemical staining Methods 0.000 description 7
- 239000012634 fragment Substances 0.000 description 6
- 239000000427 antigen Substances 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- DEQANNDTNATYII-OULOTJBUSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-n-[(2r,3r)-1,3-dihydroxybutan-2-yl]-7-[(1r)-1-hydroxyethyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxa Chemical compound C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)C1=CC=CC=C1 DEQANNDTNATYII-OULOTJBUSA-N 0.000 description 4
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 4
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 4
- 239000005511 L01XE05 - Sorafenib Substances 0.000 description 4
- 229930192392 Mitomycin Natural products 0.000 description 4
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 4
- 108010016076 Octreotide Proteins 0.000 description 4
- 238000010240 RT-PCR analysis Methods 0.000 description 4
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 4
- 229960004316 cisplatin Drugs 0.000 description 4
- 229960004679 doxorubicin Drugs 0.000 description 4
- 229960002949 fluorouracil Drugs 0.000 description 4
- 238000007901 in situ hybridization Methods 0.000 description 4
- 229960004857 mitomycin Drugs 0.000 description 4
- 229960002700 octreotide Drugs 0.000 description 4
- 229960003787 sorafenib Drugs 0.000 description 4
- 229960001603 tamoxifen Drugs 0.000 description 4
- 230000002285 radioactive effect Effects 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 210000003556 vascular endothelial cell Anatomy 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US6991008P | 2008-03-19 | 2008-03-19 | |
| US61/069,910 | 2008-03-19 | ||
| PCT/US2009/001689 WO2009117096A1 (en) | 2008-03-19 | 2009-03-18 | Methods and agents for the diagnosis and treatment of hepatocellular carcinoma |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014226127A Division JP6073850B2 (ja) | 2008-03-19 | 2014-11-06 | 肝細胞癌の診断および治療のための方法および作用物質 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011518773A JP2011518773A (ja) | 2011-06-30 |
| JP2011518773A5 true JP2011518773A5 (OSRAM) | 2012-02-23 |
| JP5882732B2 JP5882732B2 (ja) | 2016-03-09 |
Family
ID=40810188
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011500800A Active JP5882732B2 (ja) | 2008-03-19 | 2009-03-18 | 肝細胞癌の診断および治療のための方法および作用物質 |
| JP2014226127A Active JP6073850B2 (ja) | 2008-03-19 | 2014-11-06 | 肝細胞癌の診断および治療のための方法および作用物質 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014226127A Active JP6073850B2 (ja) | 2008-03-19 | 2014-11-06 | 肝細胞癌の診断および治療のための方法および作用物質 |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US8815240B2 (OSRAM) |
| EP (1) | EP2269071B1 (OSRAM) |
| JP (2) | JP5882732B2 (OSRAM) |
| KR (2) | KR101766627B1 (OSRAM) |
| CN (1) | CN102037362B (OSRAM) |
| AU (1) | AU2009226152A1 (OSRAM) |
| BR (1) | BRPI0908737B1 (OSRAM) |
| CA (1) | CA2718869C (OSRAM) |
| DK (1) | DK2269071T3 (OSRAM) |
| ES (1) | ES2527072T3 (OSRAM) |
| NZ (1) | NZ588587A (OSRAM) |
| TW (2) | TWI566779B (OSRAM) |
| WO (1) | WO2009117096A1 (OSRAM) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009117096A1 (en) | 2008-03-19 | 2009-09-24 | China Synthetic Rubber Corporation | Methods and agents for the diagnosis and treatment of hepatocellular carcinoma |
| AU2009234444A1 (en) * | 2008-04-11 | 2009-10-15 | China Synthetic Rubber Corporation | Methods, agents and kits for the detection of cancer |
| EP3199553B1 (en) * | 2008-10-29 | 2019-04-24 | Circular Commitment Company | Methods and agents for the diagnosis and treatment of hepatocellular carcinoma |
| CN103119442A (zh) * | 2010-06-03 | 2013-05-22 | 霍夫曼-拉罗奇有限公司 | 抗体和免疫偶联物的免疫peg成像及其用途 |
| WO2012140660A1 (en) | 2011-04-14 | 2012-10-18 | Exalenz Bioscience Ltd. | Methods for diagnosis, prognosis, monitoring and treatment of hepatocellular carcinoma |
| KR101463098B1 (ko) * | 2011-11-28 | 2014-11-27 | 한국생명공학연구원 | ｃ-Ｍｅｔ에 대한 인간항체에 약물이 접합된 약물 복합체 및 이의 용도 |
| CA3204283A1 (en) | 2011-12-14 | 2013-06-20 | AbbVie Deutschland GmbH & Co. KG | Composition and method for the diagnosis and treatment of iron-related disorders |
| MX356933B (es) * | 2011-12-14 | 2018-06-20 | Abbvie Deutschland | Composicion y metodo para el diagnostico y tratamiento de trastornos relacionados con hierro. |
| CN102796820B (zh) * | 2012-08-22 | 2013-12-04 | 黄曙 | 一种原发性肝细胞性肝癌相关的klotho基因单核苷酸多态性其构建方法及其应用 |
| EP2899274A4 (en) * | 2012-09-19 | 2016-06-01 | Sysmex Corp | METHOD FOR OBTAINING INFORMATION ON HEPATOCELLULAR CARCINOMAS AND MARKERS AND KIT FOR OBTAINING INFORMATION ON HEPATOCELLULAR CARCINOMAS |
| US9493552B2 (en) | 2013-11-15 | 2016-11-15 | China Synthetic Rubber Corporation | Therapeutic biologic for treatment of hepatocellular carcinoma |
| CN103911440B (zh) * | 2014-03-13 | 2015-04-22 | 南京医科大学 | 一种与铂类化疗药物肝脏毒性相关的snp标志物及其应用 |
| WO2017047762A1 (ja) * | 2015-09-18 | 2017-03-23 | 国立大学法人鳥取大学 | 低分子化合物による癌と線維化の抑制と再生促進の効果 |
| CN108997497B (zh) * | 2018-03-30 | 2022-02-25 | 华兰基因工程有限公司 | 特异结合人质膜膜泡关联蛋白pv-1的单克隆抗体及其制备方法与应用 |
| KR20230012539A (ko) | 2020-05-13 | 2023-01-26 | 디스크 메디슨, 인크. | 골수섬유증을 치료하기 위한 항-헤모주벨린 (hjv) 항체 |
| CN114107449B (zh) * | 2020-08-31 | 2024-04-09 | 中山大学孙逸仙纪念医院 | 一种单细胞内原位qPCR方法 |
| CN115925805B (zh) * | 2022-07-08 | 2023-12-22 | 华兰基因工程(河南)有限公司 | 一种人质膜膜泡关联蛋白pv-1融合蛋白及其制备方法 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US6749853B1 (en) | 1992-03-05 | 2004-06-15 | Board Of Regents, The University Of Texas System | Combined methods and compositions for coagulation and tumor treatment |
| HU220347B (hu) | 1994-07-11 | 2001-12-28 | Board Of Regents The University Of Texas System | Készítmény az érrendszer specifikus koagulálásához |
| KR100565883B1 (ko) | 1997-01-22 | 2006-03-31 | 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 | 응고 및 종양 치료용 조직 인자 방법 및 조성물 |
| US20040067490A1 (en) | 2001-09-07 | 2004-04-08 | Mei Zhong | Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
| AU1181802A (en) * | 2000-09-27 | 2002-04-08 | Curagen Corp | Novel proteins and nucleic acids encoding same |
| DE10136273A1 (de) | 2001-07-25 | 2003-02-13 | Sabine Debuschewitz | Molekulare Marker beim hepatozellulären Karzinom |
| JP2005536439A (ja) * | 2001-09-18 | 2005-12-02 | ジェネンテック・インコーポレーテッド | 腫瘍の診断及び治療のための組成物と方法 |
| CA2603730A1 (en) | 2005-03-31 | 2006-10-05 | Calando Pharmaceuticals, Inc. | Inhibitors of ribonucleotide reductase subunit 2 and uses thereof |
| WO2006110593A2 (en) | 2005-04-07 | 2006-10-19 | Macrogenics, Inc. | Biological targets for the diagnosis, treatment and prevention of cancer |
| WO2008091781A1 (en) | 2007-01-22 | 2008-07-31 | Mayo Foundation For Medical Education And Research | Reducing tumor growth |
| WO2009117096A1 (en) | 2008-03-19 | 2009-09-24 | China Synthetic Rubber Corporation | Methods and agents for the diagnosis and treatment of hepatocellular carcinoma |
| AU2009234444A1 (en) | 2008-04-11 | 2009-10-15 | China Synthetic Rubber Corporation | Methods, agents and kits for the detection of cancer |
| WO2010021822A2 (en) | 2008-07-30 | 2010-02-25 | The Regents Of The University Of California | Discovery of candidate biomarkers of in vivo apoptosis by global profiling of caspase cleavage sites |
| EP3199553B1 (en) | 2008-10-29 | 2019-04-24 | Circular Commitment Company | Methods and agents for the diagnosis and treatment of hepatocellular carcinoma |
| JP2013503140A (ja) | 2009-08-27 | 2013-01-31 | ノヴォ ノルディスク アー／エス | 活性化血小板に対する組織因子の標的化 |
| US9493552B2 (en) | 2013-11-15 | 2016-11-15 | China Synthetic Rubber Corporation | Therapeutic biologic for treatment of hepatocellular carcinoma |
-
2009
- 2009-03-18 WO PCT/US2009/001689 patent/WO2009117096A1/en not_active Ceased
- 2009-03-18 BR BRPI0908737-0A patent/BRPI0908737B1/pt active IP Right Grant
- 2009-03-18 EP EP09723224.3A patent/EP2269071B1/en active Active
- 2009-03-18 CA CA2718869A patent/CA2718869C/en active Active
- 2009-03-18 JP JP2011500800A patent/JP5882732B2/ja active Active
- 2009-03-18 KR KR1020177005386A patent/KR101766627B1/ko active Active
- 2009-03-18 AU AU2009226152A patent/AU2009226152A1/en not_active Abandoned
- 2009-03-18 KR KR1020107023301A patent/KR101713339B1/ko active Active
- 2009-03-18 DK DK09723224.3T patent/DK2269071T3/en active
- 2009-03-18 ES ES09723224.3T patent/ES2527072T3/es active Active
- 2009-03-18 US US12/933,248 patent/US8815240B2/en active Active
- 2009-03-18 CN CN200980118081.2A patent/CN102037362B/zh active Active
- 2009-03-18 NZ NZ588587A patent/NZ588587A/xx unknown
- 2009-03-19 TW TW104103866A patent/TWI566779B/zh active
- 2009-03-19 TW TW098108921A patent/TWI476002B/zh active
-
2014
- 2014-07-18 US US14/335,129 patent/US9545443B2/en active Active
- 2014-11-06 JP JP2014226127A patent/JP6073850B2/ja active Active
-
2016
- 2016-12-06 US US15/370,711 patent/US10370445B2/en active Active
-
2019
- 2019-06-24 US US16/450,730 patent/US11339217B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011518773A5 (OSRAM) | ||
| US10174123B2 (en) | Antibody and binding fragment recognizing CACNA2D1 and use thereof | |
| DK2269071T3 (en) | METHOD AND REAGENTS FOR DIAGNOSIS AND TREATMENT OF HEPATOCELLULAR CARCINOM | |
| JP2013531655A5 (OSRAM) | ||
| JP7763850B2 (ja) | ＰＤＧＦＲα阻害剤でがんを治療する方法 | |
| US20140322234A1 (en) | Analysis and Targeting of ROR2 in Cancer | |
| EP3199553B1 (en) | Methods and agents for the diagnosis and treatment of hepatocellular carcinoma | |
| CA2592330A1 (en) | Gitr antibodies for the diagnosis of nsclc | |
| WO2019126594A2 (en) | Antibodies to centrin-1, methods of making, and uses thereof | |
| CN113508141B (zh) | 抗体及其功能片段 | |
| JP2025533015A (ja) | 薬物抵抗性肝細胞癌の処置 | |
| WO2006078780A2 (en) | Rdc1 antibodies for the diagnosis of nsclc | |
| HK1241894B (en) | Methods and agents for the diagnosis and treatment of hepatocellular carcinoma | |
| HK1152670A (en) | Therapeutic use of anti-tweak receptor antibodies | |
| HK1149322B (en) | Methods and agents for the diagnosis and treatment of hepatocellular carcinoma | |
| HK1157352A (en) | Methods and agents for the diagnosis and treatment of hepatocellular carcinoma | |
| HK1157352B (en) | Methods and agents for the diagnosis and treatment of hepatocellular carcinoma |